Bollard Group’s Disc Medicine IRON Stock Holding History

Bollard Group’s Portfolio IRON Stock Details IRON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-30,635	Closed	-$1.62M	–	284
2025 Q2	$1.62M	Buy	+30,635	New	+$1.44M	0.04%	99

Other funds holding IRON

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bollard Group's IRON Position: Q3 2025 in Review

Bollard Group sold out of Disc Medicine (IRON) in Q3 2025, closing a stake of 30,635 shares — an estimated $1.62M sold.

Bollard Group first reported a position in IRON in Q2 2025 and held it in 1 quarter. The position peaked at $1.62M in Q2 2025. 168 funds tracked by Wall St. Rank hold IRON as of Q3 2025.

Bollard Group reported no remaining Disc Medicine position as of Q3 2025 after selling out during the quarter.
Bollard Group sold 30,635 Disc Medicine shares in Q3 2025, an estimated $1.62M.
Bollard Group first reported a position in Disc Medicine in Q2 2025 and held it in 1 quarter.
Bollard Group's Disc Medicine position peaked at $1.62M in Q2 2025.
168 funds tracked by Wall St. Rank held Disc Medicine as of Q3 2025.

Based on Bollard Group's 13F filing for Q3 2025, filed 14 Nov 2025.